Volume | 109,879 |
|
|||||
News | - | ||||||
Day High | 14.815 | Low High |
|||||
Day Low | 13.83 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Adverum Biotechnologies Inc | ADVM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
14.63 | 13.83 | 14.815 | 14.14 | 14.66 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,791 | 109,879 | US$ 14.34 | US$ 1,575,864 | - | 6.81 - 29.80 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:09:04 | 1 | US$ 13.86 | USD |
Adverum Biotechnologies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.42B | 101.03M | - | 0 | -154.54M | -1.53 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Adverum Biotechnologies News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADVM Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.69 | 17.65 | 13.67 | 14.95 | 408,010 | -1.55 | -9.88% |
1 Month | 19.80 | 20.90 | 13.67 | 17.50 | 1,638,449 | -5.66 | -28.59% |
3 Months | 8.589 | 29.80 | 8.00 | 18.44 | 2,304,713 | 5.55 | 64.63% |
6 Months | 16.70 | 29.80 | 7.40 | 17.34 | 1,214,327 | -2.56 | -15.33% |
1 Year | 7.848 | 29.80 | 6.81 | 16.80 | 804,672 | 6.29 | 80.17% |
3 Years | 99.20 | 108.50 | 5.31 | 22.75 | 1,222,203 | -85.06 | -85.75% |
5 Years | 52.10 | 269.80 | 5.31 | 61.50 | 1,210,581 | -37.96 | -72.86% |
Adverum Biotechnologies Description
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single in-office intravitreal IVT injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust sustained treatment response reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor VEGF injections. |